Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

BACKGROUND: Nilotinib (Tasigna®) is a second-generation tyrosine kinase inhibitor that shows faster and deeper molecular responses (MR) in comparison to Imatinib as initial therapy in chronic phase chronic myeloid leukemia (CML). Efficacy and safety data for nilotinib in the Asian population is scar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaidi, Uzma, Kaleem, Bushra, Borhany, Munira, Maqsood, Sidra, Fatima, Naveena, Sufaida, Gul, Ansari, Saqib Hussain, Farzana, Tasneem, Shamsi, Tahir Sultan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388993/
https://www.ncbi.nlm.nih.gov/pubmed/30863159
http://dx.doi.org/10.2147/CMAR.S181911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388993/
https://www.ncbi.nlm.nih.gov/pubmed/30863159
http://dx.doi.org/10.2147/CMAR.S181911

Ejemplares similares